House & Home
Fri, July 27, 2012Thu, July 26, 2012Wed, July 25, 2012Tue, July 24, 2012Mon, July 23, 2012Fri, July 20, 2012Thu, July 19, 2012Wed, July 18, 2012Tue, July 17, 2012Mon, July 16, 2012Sat, July 14, 2012Fri, July 13, 2012Thu, July 12, 2012Wed, July 11, 2012Tue, July 10, 2012Mon, July 9, 2012Sun, July 8, 2012Fri, July 6, 2012Thu, July 5, 2012Wed, July 4, 2012Tue, July 3, 2012Mon, July 2, 2012Sun, July 1, 2012Fri, June 29, 2012Thu, June 28, 2012Wed, June 27, 2012Tue, June 26, 2012Mon, June 25, 2012Fri, June 22, 2012Thu, June 21, 2012Wed, June 20, 2012FDA Approves OncoVista's Phase I Clinical Trial of New Drug Candidate (OVI-117) for Solid Tumors
//house-home.news-articles.net/content/2012/07/1 .. new-drug-candidate-ovi-117-for-solid-tumors.html
Published in House and Home on Tuesday, July 10th 2012 at 5:09 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
July 10, 2012 08:00 ET
FDA Approves OncoVista's Phase I Clinical Trial of New Drug Candidate (OVI-117) for Solid Tumors
SAN ANTONIO, TX--(Marketwire - Jul 10, 2012) - OncoVista Innovative Therapies, Inc. (
"The FDA's swift approval of our IND provides validation of OncoVista's mission to be a leader in the development of more efficacious and less toxic targeted cancer therapies," said Alexander Weis, PhD., Chairman, President and CEO of OncoVista. This will allow the Company to build and enhance our drug portfolio to the benefit of shareholders and more importantly, patients. The founding mission of OncoVista is to develop more effective and less toxic drugs for cancer. This is an important milestone towards that mission.
About OVI-117
OVI-117, a derivative of FdUMP/5-FU, is a Thymidylate Synthase (TS) inhibitor with enhanced pharmacological properties resulting in the retention of efficacy and the reduction of toxicity. It has particular promise for colon, breast, gastric and prostate tumors.
About OncoVista Innovative Therapies
Texas-based OncoVista Innovative Therapies, Inc. (
Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. These risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements.
